×
About 653 results

ALLMedicine™ Keratoconjunctivitis Sicca Center

Research & Reviews  195 results

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
https://clinicaltrials.gov/ct2/show/NCT04440280

Jan 26th, 2023 - Fuchs Endothelial Corneal Dystrophy (FECD) is the most common corneal endothelial disorder and has been estimated to affect approximately 4% of the US population over the age of 40. Corneal transplantation is currently the primary treatment modali...

Giant Papillary Conjunctivitis
https://emedicine.medscape.com/article/1191641-print

Jan 24th, 2023 - Practice Essentials Giant papillary conjunctivitis (GPC), also called contact lens–induced papillary conjunctivitis (CLPC), is a common complication of contact lens wear.[1] First described by Spring,[2, 3, 4, 5] GPC is characterized by hypersensi...

Giant Papillary Conjunctivitis
http://emedicine.medscape.com/article/1191641-overview

Jan 24th, 2023 - Practice Essentials Giant papillary conjunctivitis (GPC), also called contact lens–induced papillary conjunctivitis (CLPC), is a common complication of contact lens wear. [1] First described by Spring, [2, 3, 4, 5] GPC is characterized by hypersen...

Giant Papillary Conjunctivitis
https://emedicine.medscape.com/article/1191641-overview

Jan 24th, 2023 - Practice Essentials Giant papillary conjunctivitis (GPC), also called contact lens–induced papillary conjunctivitis (CLPC), is a common complication of contact lens wear. [1] First described by Spring, [2, 3, 4, 5] GPC is characterized by hypersen...

PACK syndrome: A case series and review.
https://doi.org/10.1016/j.amjms.2022.12.005
The American Journal of the Medical Sciences; Collins B, Dillon D et. al.

Dec 20th, 2022 - A rare overlap syndrome between CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) syndrome and primary biliary cholangitis (PBC) is described as PACK syndrome, an acronym for primary biliary cholangi...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  34 results

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
https://clinicaltrials.gov/ct2/show/NCT04440280

Jan 26th, 2023 - Fuchs Endothelial Corneal Dystrophy (FECD) is the most common corneal endothelial disorder and has been estimated to affect approximately 4% of the US population over the age of 40. Corneal transplantation is currently the primary treatment modali...

Intra-Nasal Mechanical Stimulation (INMEST) as a Treatment of Keratoconjunctivitis Sicca (Dry Eye Syndrome)
https://clinicaltrials.gov/ct2/show/NCT03418259

Dec 13th, 2022 - The purpose of the study is to evaluate how treatment with Intra-Nasal Mechanical Stimulation (INMEST) in the nasal cavity in patients with Keratoconjunctivitis sicca can relieve these symtoms.

HRR as a Novel Biomarker in Sjögren's Syndrome
https://clinicaltrials.gov/ct2/show/NCT05633524

Dec 2nd, 2022 - Sjögren's syndrome (SS) is an autoimmune disorder characterized by chronic salivary and lacrimal gland dysfunction leading to dry mouth (xerostomia) and dry eye (xerophthalmia) sensation (1). Although dry mouth and dry eye are the main symptoms, t...

Platelet Rich Plasma in Corneal Surface Diseases
https://clinicaltrials.gov/ct2/show/NCT05320172

Sep 19th, 2022 - There are many conditions in which the ocular surface is severely affected as keratoconjunctivitis sicca, persistent epithelial corneal defect, recurrent corneal erosion, neurotrophic keratopathy, post laser in-situ keratomileusis (LASIK) ocular s...

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
https://clinicaltrials.gov/ct2/show/NCT02688556

Aug 29th, 2022 - This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.

see more →

News  16 results

Fast Five Quiz: Dry Eye Disease (Keratoconjunctivitis Sicca) Etiology and Pathophysiology
https://www.medscape.com/viewarticle/982258

Nov 10th, 2022 - Dry eye disease (DED), also known as dry eye syndrome, keratoconjunctivitis sicca (KCS), and keratitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film. It often results in ocular symptoms and ...

FDA Approves First Generic Version of Restasis for Dry Eye
https://www.medscape.com/viewarticle/967849

Feb 3rd, 2022 - The US Food and Drug Administration (FDA) has approved the first generic of cyclosporine ophthalmic emulsion (Restasis) to treat keratoconjunctivitis sicca (dry eye). Restasis has been approved by the FDA since 2003 and works to help increase tear...

FDA Approves First Generic of Restasis for Dry Eye
https://www.medpagetoday.com/ophthalmology/generalophthalmology/96989

Feb 2nd, 2022 - The FDA approved the first generic of cyclosporine ophthalmic emulsion (Restasis) for dry eye, a condition that affects millions of Americans each year. Cyclosporine ophthalmic emulsion is a commonly prescribed immunomodulator with anti-inflammato...

Fast Five Quiz: Psoriatic Arthritis Presentation and Diagnosis
https://reference.medscape.com/viewarticle/922805_4

Jan 29th, 2020 - Recognizing the patterns of joint involvement seen in psoriatic arthritis is essential to its diagnosis. Five patterns have been identified. They are: Asymmetrical oligoarticular arthritis Symmetrical polyarthritis Arthritis mutilans Distal interp...

FDA Clears New Treatment for Dry Eye (Cequa)
https://www.medscape.com/viewarticle/900888

Aug 17th, 2018 - The US Food and Drug Administration (FDA) has approved cyclosporine A ophthalmic solution 0.09% (Cequa, Sun Pharmaceuticals) to increase tear production in patients with keratoconjunctivitis sicca (dry eye), the company has announced. Cequa is a p...

see more →

Patient Education  1 results see all →